SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (NasdaqGM:OPTR - News) announced today that the underwriters of the company’s recent initial public offering of common stock have exercised an over-allotment option to purchase an additional 1,050,000 shares of the company’s common stock from Par Pharmaceutical Companies, Inc. Par is the sole selling stockholder in this offering. Par sold the shares at a public offering price of $7.00 per share, resulting in estimated net proceeds to Par of approximately $6.8 million.
